• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Graphite Bio de­buts cor­po­rate brand cam­paign with ‘Cure’ as­pi­ra­tions, even years ahead of drug ap­proval

3 years ago
Pharma
Marketing

Sen­ate pro­pos­es $16B to fund the next wave of Covid-19 vac­cines, ther­a­peu­tics in 2023

3 years ago
FDA+
Coronavirus

Man­u­fac­tur­ing roundup: Gen­Bio­Pro looks to counter Mis­sis­sip­pi trig­ger law; Pis­gah Labs to in­vest $55M in NC ex­pan­sion ...

3 years ago
Manufacturing

Af­ter net­ting $200M, Syn­thego to break ground on its man­u­fac­tur­ing fa­cil­i­ty

3 years ago
Cell/Gene Tx
Manufacturing

PCI Phar­ma com­mits to a mul­ti­mil­lion-dol­lar ex­pan­sion of its man­u­fac­tur­ing fa­cil­i­ty in Wales

3 years ago
Pharma
Manufacturing

David Li­u's lab de­vel­ops next-gen base ed­i­tors, small enough to fit in­to sin­gle AAV

3 years ago
R&D
Discovery

Io­n­is, Cy­cle­ri­on tout pos­i­tive da­ta read­outs; MA­IA prices first biotech IPO in over two months

3 years ago
News Briefing

El­e­va­tion On­col­o­gy dips its toes in­to AD­Cs, adding sec­ond drug to its bag. But is it pit­ting it­self against Bris­tol ...

3 years ago
R&D

What can Mer­ck af­ford to buy now? ‘ANY­THING’ it wants

3 years ago
Deals
Bioregnum

Small Penn­syl­va­nia biotech lays off a fourth of its staff as it tries to nav­i­gate com­mer­cial land­scape

3 years ago
People

Take­da ax­es clin­i­cal-stage pro­gram in $1B+ Turn­stone Bi­o­log­ics col­lab­o­ra­tion

3 years ago
Pharma

Lex­i­con hops on pub­lic of­fer­ing train to pre­pare for next year's po­ten­tial drug ap­proval

3 years ago
Financing

Two groups look to bring stan­dard­iza­tion to cell ther­a­py man­u­fac­tur­ing in their lat­est pa­per

3 years ago
Manufacturing

Up­dat­ed: Deep­Mind's Al­phaFold now con­tains struc­ture of 200M pro­teins. What does that mean for drug R&D?

3 years ago
R&D
AI

Lab­corp is spin­ning out its clin­i­cal de­vel­op­ment unit in ma­jor shake­up

3 years ago
Deals
Manufacturing

'Tip of the ice­berg': No­var­tis-part­nered UC Berke­ley lab churns out a start­up to tack­le pro­tein sta­bi­liza­tion

3 years ago
Financing
Startups

Manchin strikes again: Rec­on­cil­i­a­tion pack­age sur­faces, with drug pric­ing re­forms ful­ly in­tact — for now

3 years ago
Pharma
Law

Two sides of 'his­toric' drug pric­ing bill: Phar­ma in­dus­try blasts 'mis­take' while ad­vo­cates plan for 'first ever' ...

3 years ago
Pharma

Warn­ing let­ter is­sued to New Jer­sey gener­ics man­u­fac­tur­er over qual­i­ty con­trol is­sues

3 years ago
Pharma
FDA+

Sen­ate Fi­nance chair calls on Mer­ck and Ab­bott to com­ply with his in­ves­ti­ga­tion in­to their off­shore tax schemes

3 years ago
Pharma
Law

More deals ahead for Bris­tol My­ers? CEO Gio­van­ni Caforio touts 'size ag­nos­tic' BD strat­e­gy

3 years ago
Deals
Pharma

EMA re­views re­pur­posed ex­per­i­men­tal can­cer drug for Covid-19, even with­out a sub­mis­sion

3 years ago
Coronavirus

Bavar­i­an Nordic's Dan­ish fa­cil­i­ty gets FDA thumbs up to ex­pand mon­key­pox vac­cine pro­duc­tion

3 years ago
Pharma
FDA+

With Ver­tex and CRISPR some 30 pa­tients in, Ed­i­tas moves for­ward in sick­le cell pa­tients af­ter FDA lifts hold

3 years ago
R&D
First page Previous page 483484485486487488489 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times